Glycine Evonik Expands Glycine Capacity in China
Evonik Industries has increased its production capacity for the pharmaceutical amino acid glycine by 50 percent. This was achieved only by efficiency gains in the production process.
Nanning, PR China – Germany-based Evonik Industries has increased its production capacity for the pharmaceutical amino acid glycine by 50 percent due to rising demand by optimizing the production process.
By upgrading its technologies particularly in the purification process, Evonik has further improved product quality. “We’re now able to provide glycine in all crystalline forms and particle size distributions requested by customers," notes Dr. Jean-Louis Philippe, the responsible marketing manager for the pharmaceutical amino acids.
Evonik is a major provider of glycine and manufactures the amino acid at its Chinese Nanning site in accordance with the requirements of cGMP (current Good Manufacturing Practice) and the European Pharmacopoeia (CEP; Certificate of Suitability of Monographs of the European Pharmacopoeia). The company is investing in a new plant there to expand its portfolio of specialty chemical products by milling and sieving processes. The new qualities are expected to come on the market at the end of the year.